Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. The Company is engaged in research and product development activities. The Company is evaluating its lead platform product, MultiStem, in Phase II clinical trials and an investigator-led Phase I trial. The Company clinical development program includes Inflammatory Bowel Disease, Ischemic Stroke, Acute Myocardial Infarction and Hematopoietic Stem Cell Transplant/GvHD. The Company is conducting double blind, placebo controlled trial with the partner Pfizer, in ulcerative colitis patients. The Company is conducting double blind, placebo-controlled trial for the treatment of Ischemic Stroke. The Company is engaged in preclinical development and evaluation of MultiStem therapy in inflammatory and immune, neurological and cardiovascular diseases. The Company is also engaged in the development of small molecule therapies to treat obesity and schizophrenia.